Long non-coding RNAs: From disease code to drug role

• Main Authors: Yuanyuan Chen, Zhaojun Li, Xiaoguang Chen, Sen Zhang
• Format: Article
• Language: English
• Published: Elsevier 2021-02-01
• Series: Acta Pharmaceutica Sinica B
• Subjects: LncRNAs; Targeted drug; Gene therapy; Small molecules; Delivery; ASncmtRNA
• Online Access: http://www.sciencedirect.com/science/article/pii/S2211383520307346

Enormous studies have corroborated that long non-coding RNAs (lncRNAs) extensively participate in crucial physiological processes such as metabolism and immunity, and are closely related to the occurrence and development of tumors, cardiovascular diseases, nervous system disorders, nephropathy, and other diseases. The application of lncRNAs as biomarkers or intervention targets can provide new insights into the diagnosis and treatment of diseases. This paper has focused on the emerging research into lncRNAs as pharmacological targets and has reviewed the transition of lncRNAs from the role of disease coding to acting as drug candidates, including the current status and progress in preclinical research. Cutting-edge strategies for lncRNA modulation have been summarized, including the sources of lncRNA-related drugs, such as genetic technology and small-molecule compounds, and related delivery methods. The current progress of clinical trials of lncRNA-targeting drugs is also discussed. This information will form a latest updated reference for research and development of lncRNA-based drugs.